Apo-Fluoxetine Recall Due to Impurities

Source: Health Canada · Canada

Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.

Health Canada has recalled specific lots of Apo-Fluoxetine capsules because impurities are out of specification and out of trend, potentially affecting product safety.

What this Health Canada recall tells you, and what most readers miss

This notice was issued by Health Canada on April 10, 2026 and geographically references Canada. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, medication.

Apo-Fluoxetine Recall

What Happened

Health Canada has issued a recall for Apo-Fluoxetine because the impurities in the affected lots are out of specification and out of trend.

Which Products Are Affected

The affected products include:

  • Apo-Fluoxetine 20mg, with DIN 02216361, capsule form, strength of Fluoxetine (Fluoxetine hydrochloride) 20mg, and lots VM4608 and VM4612.
  • Apo-Fluoxetine 10mg, with DIN 02216353, capsule form, strength of Fluoxetine (Fluoxetine hydrochloride) 10mg, and lot VM4598. These products are manufactured by Apotex Inc., and the recall applies to retailers.

What You Should Do

Verify if your product is affected by checking the lot numbers. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada, and report any other health product safety complaints to Health Canada.

Why This Matters

This recall addresses potential risks associated with impurities in medication, ensuring consumer safety and the integrity of health products.

Source

Health Canada Recall Alert

Original source: Health Canada Official Notice ↗

All Product & Food Recalls →

Nationwide notices with similar length or severity timing 8

Two Areazine-derived peer sets for this Health Canada recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Frequently Asked Questions

Common questions about this Health Canada recall.

What is this Health Canada recall about?
Health Canada has recalled specific lots of Apo-Fluoxetine capsules because impurities are out of specification and out of trend, potentially affecting product safety.
Which agency issued this alert?
This alert was issued by Health Canada. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects Canada. Check with Health Canada for the most current geographic scope.
Where can I find more Product & Food Recalls updates?
Browse the full Product & Food Recalls feed on Areazine at areazine.com/ca/recalls/ for the latest updates from Health Canada and other agencies.